Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer:

Xiaotong Lu; Jingbo Wang; Chunyu Wang; Jun Liang; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Zefen Xiao; Zhouguang Hui; Jima Lu; Tao Zhang; Wenyang Liu; Jianyang Wang; Xin Wang; Lei Deng; Yirui Zhai; Nan Bi; Luhua Wang

doi:10.1177/11795549221080347

Lu, Xiaotong; Wang, Jingbo; Wang, Chunyu; Liang, Jun; Zhou, Zongmei; Chen, Dongfu; Feng, Qinfu; Xiao, Zefen; Hui, Zhouguang; Lu, Jima; Zhang, Tao; Liu, Wenyang; Wang, Jianyang; Wang, Xin; Deng, Lei; Zhai, Yirui; Bi, Nan; Wang, Luhua

2022-02-26 00:00:00

Background: EGFR tyrosine kinase inhibitor (TKI) is recommended as the first-line therapy for patients with EGFR-mutant metastatic non-small cell lung cancer (NSCLC). Yet, resistance often occurs in 1 year after therapy and most progressions occur at the initial sites of disease. Addition of local therapy to the first-line TKI therapy may delay the progression and provide survival benefit to the patients. Methods: From 2010 to 2017, metastatic NSCLC patients with EGFR activating mutations who received first-line TKI and relatively radical local therapy (RRLT) were reviewed. RRLT was defined as local curative therapy to the main site or any intensity of local therapy to all sites of disease. The Kaplan-Meier method and log-rank test were used for survival estimation and comparison. Results: A total of 45 patients were included in this retrospective study with a median follow-up of 48.0 months. The median progression-free survival (PFS) and overall survival (OS) was 17.0 months (95% confidence interval [CI]: 14.6-19.3) and 55.0 months (95% CI: 49.3-60.6), respectively. Univariate analysis indicated that age ⩽ 60 years (P = .019), first-line TKI duration ⩾ 10 months (P = .028), and accumulated TKI duration ⩾ 20 months (P = .016) were significantly associated with favorable OS. Among the 36 patients who progressed during the follow-up, 55.8% of the progressions occurred at the new sites. RRLT combined with TKI did not show any severe toxicity to the patients. Conclusions: Combined application of RRLT and first-line TKI may improve the survival and alter the pattern of failure for metastatic NSCLC patients with EGFR activating mutations.

http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Clinical Medicine Insights: Oncology SAGE

http://www.deepdyve.com/lp/sage/local-therapy-combined-with-first-line-egfr-tyrosine-kinase-inhibitor-0YRQmlgv0q

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer:

Lu, Xiaotong; Wang, Jingbo; Wang, Chunyu; Liang, Jun; Zhou, Zongmei;

Clinical Medicine Insights: Oncology , Volume 16: 1 – Feb 26, 2022

Abstract

References (60)

( LimSM SynNL ChoBC SooRA . Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1-10.29477930)

LimSM SynNL ChoBC SooRA . Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1-10.29477930

LimSM SynNL ChoBC SooRA . Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1-10.29477930, LimSM SynNL ChoBC SooRA . Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1-10.29477930

( IyengarP WardakZ GerberDE , et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501.)

IyengarP WardakZ GerberDE , et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501.

IyengarP WardakZ GerberDE , et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501., IyengarP WardakZ GerberDE , et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501.

R. Wang, Tao Li, J. Lv, Chang Sun, Q. Shi (2019)

Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer.

Journal of Clinical Oncology

D. Palma, R. Olson, S. Harrow, S. Gaede, A. Louie, C. Haasbeek, L. Mulroy, M. Lock, G. Rodrigues, B. Yaremko, D. Schellenberg, B. Ahmad, G. Griffioen, S. Senthi, A. Swaminath, N. Kopek, Mitchell Liu, K. Moore, S. Currie, G. Bauman, A. Warner, S. Senan (2019)

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

The Lancet, 393

B. Qiu, Ying-ying Liang, Qi-wen Li, Guihong Liu, F. Wang, Z. Chen, Mengzhong Liu, Ming Zhao, Hui Liu (2017)

Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non–small‐cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation

Clinical Lung Cancer, 18

( ChangCC ChiKH KaoSJ , et al. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer. 2011;73:189-194.21247653)

ChangCC ChiKH KaoSJ , et al. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer. 2011;73:189-194.21247653, ChangCC ChiKH KaoSJ , et al. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer. 2011;73:189-194.21247653

( GrayPJ MakRH YeapBY , et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer. 2014;85:239-244.24974152)

GrayPJ MakRH YeapBY , et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer. 2014;85:239-244.24974152, GrayPJ MakRH YeapBY , et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer. 2014;85:239-244.24974152

( WeickhardtAJ ScheierB BurkeJM , et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807-1814.23154552)

WeickhardtAJ ScheierB BurkeJM , et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807-1814.23154552, WeickhardtAJ ScheierB BurkeJM , et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807-1814.23154552

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

( ElaminYY GomezDR AntonoffMB , et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2019;20:43-47.30343004)

ElaminYY GomezDR AntonoffMB , et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2019;20:43-47.30343004, ElaminYY GomezDR AntonoffMB , et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2019;20:43-47.30343004

( QiuB LiangY LiQ , et al. Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin Lung Cancer. 2017;18:e369-e373.)

QiuB LiangY LiQ , et al. Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin Lung Cancer. 2017;18:e369-e373., QiuB LiangY LiQ , et al. Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin Lung Cancer. 2017;18:e369-e373.

Chih-Chia Chang, K. Chi, S. Kao, Pei-Sung Hsu, Y. Tsang, Heng-Jui Chang, Y. Yeh, Y. Hsieh, Jiunn-Song Jiang (2011)

Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.

Lung cancer, 73 2

( PatelSH RimnerA FosterA , et al. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer. 2017;108:109-114.28625621)

PatelSH RimnerA FosterA , et al. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer. 2017;108:109-114.28625621

PatelSH RimnerA FosterA , et al. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer. 2017;108:109-114.28625621, PatelSH RimnerA FosterA , et al. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer. 2017;108:109-114.28625621

( YangJJ ZhouC HuangY , et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017;5:707-716.28734822)

YangJJ ZhouC HuangY , et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017;5:707-716.28734822, YangJJ ZhouC HuangY , et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017;5:707-716.28734822

J. Yang, Yi-long Wu, Valorie Chan, J. Kurnianda, K. Nakagawa, N. Saijo, M. Fukuoka, G. McWalter, R. McCormack, T. Mok (2014)

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).

Lung cancer, 83 2

( BrayF FerlayJ SoerjomataramI SiegelRL TorreLA JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.30207593)

BrayF FerlayJ SoerjomataramI SiegelRL TorreLA JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.30207593, BrayF FerlayJ SoerjomataramI SiegelRL TorreLA JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.30207593

( ArdizzoniA BoniL TiseoM , et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847-857.17551145)

ArdizzoniA BoniL TiseoM , et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847-857.17551145, ArdizzoniA BoniL TiseoM , et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847-857.17551145

( YangJC WuYL ChanV , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014;83:174-181.24361280)

YangJC WuYL ChanV , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014;83:174-181.24361280, YangJC WuYL ChanV , et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014;83:174-181.24361280

Linpeng Zheng, Yanmei Wang, Zihan Xu, Qiao Yang, Guangkuo Zhu, Xing-Yun Liao, Xie-Wan Chen, B. Zhu, Y. Duan, Jianguo Sun (2019)

Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations

The Oncologist, 24

( WuYL ZhouC HuCP , et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213-222.24439929)

WuYL ZhouC HuCP , et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213-222.24439929, WuYL ZhouC HuCP , et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213-222.24439929

William Magnuson, N. Lester-Coll, Abraham Wu, T. Yang, Natalie Lockney, Naamit Gerber, K. Beal, A. Amini, T. Patil, Brian Kavanagh, D. Camidge, Steve Braunstein, Lauren Boreta, Suresh Balasubramanian, M. Ahluwalia, Niteshkumar Rana, A. Attia, S. Gettinger, J. Contessa, James Yu, Veronica Chiang (2017)

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 10

( PalmaDA OlsonR HarrowS , et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051-2058.30982687)

PalmaDA OlsonR HarrowS , et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051-2058.30982687, PalmaDA OlsonR HarrowS , et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051-2058.30982687

Qinghua Xu, Hui Liu, S. Meng, T. Jiang, Xue-Fei Li, S. Liang, S. Ren, Caicun Zhou (2019)

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease

Journal of Cancer, 10

M. Reck, S. Popat, Niels Reinmuth, D. Ruysscher, Keith Kerr, S. Peters (2012)

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology, 25 Suppl 3

A. Weickhardt, B. Scheier, J. Burke, G. Gan, Xian Lu, P. Bunn, D. Aisner, L. Gaspar, B. Kavanagh, R. Doebele, D. Camidge (2012)

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology, 7

( XuQ LiuH MengS , et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019;10:522-529.30719148)

XuQ LiuH MengS , et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019;10:522-529.30719148, XuQ LiuH MengS , et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019;10:522-529.30719148

M. Campo, H. Al-Halabi, M. Khandekar, A. Shaw, L. Sequist, H. Willers (2016)

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

The oncologist, 21 8

( WangR LiT LvJ SunC ShiQ . Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer (2019 ASCO annual meeting). J Clin Oncol 2019;37:e20694.)

WangR LiT LvJ SunC ShiQ . Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer (2019 ASCO annual meeting). J Clin Oncol 2019;37:e20694.

WangR LiT LvJ SunC ShiQ . Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer (2019 ASCO annual meeting). J Clin Oncol 2019;37:e20694., WangR LiT LvJ SunC ShiQ . Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer (2019 ASCO annual meeting). J Clin Oncol 2019;37:e20694.

P. Borghetti, M. Bonù, R. Giubbolini, N. Levra, R. Mazzola, M. Perna, L. Visani, F. Meacci, M. Taraborrelli, L. Triggiani, D. Franceschini, C. Greco, A. Bruni, S. Magrini, V. Scotti (2019)

Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group

La radiologia medica, 124

( NCCN Clinical Practice Guidelines in Oncology-Non-Small Cell Lung Cancer (2021 Version 7) [EB/OL]. Fort Washington: NCCN, 2021[2021-10-29]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

NCCN Clinical Practice Guidelines in Oncology-Non-Small Cell Lung Cancer (2021 Version 7) [EB/OL]. Fort Washington: NCCN, 2021[2021-10-29]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, NCCN Clinical Practice Guidelines in Oncology-Non-Small Cell Lung Cancer (2021 Version 7) [EB/OL]. Fort Washington: NCCN, 2021[2021-10-29]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

( BorghettiP BonùML GiubboliniR , et al. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiol Med. 2019;124:662-670.30771218)

BorghettiP BonùML GiubboliniR , et al. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiol Med. 2019;124:662-670.30771218, BorghettiP BonùML GiubboliniR , et al. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiol Med. 2019;124:662-670.30771218

( Al-HalabiH SayeghK DigamurthySR , et al. Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10:1601-1607.26313684)

Al-HalabiH SayeghK DigamurthySR , et al. Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10:1601-1607.26313684, Al-HalabiH SayeghK DigamurthySR , et al. Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10:1601-1607.26313684

Qinghua Xu, F. Zhou, Hui Liu, T. Jiang, Xue-Fei Li, Ya-ping Xu, Caicun Zhou (2018)

Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First‐Line EGFR‐TKIs

Journal of Thoracic Oncology, 13

( ReckM PopatS ReinmuthN , et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii27-39.)

ReckM PopatS ReinmuthN , et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii27-39.

ReckM PopatS ReinmuthN , et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii27-39., ReckM PopatS ReinmuthN , et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii27-39.

S. Lim, N. Syn, B. Cho, R. Soo (2018)

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.

Cancer treatment reviews, 65

Jun Liang, N. Bi, S. Wu, Ming Chen, C. Lv, L. Zhao, A. Shi, Wei Jiang, Yang Xu, Zongmei Zhou, Wenqing Wang, Dong-fu Chen, Z. Hui, J. Lv, Hang Zhang, Q. Feng, Z. Xiao, Xin Wang, Lipin Liu, Tao Zhang, Li-Juan Du, Wei Chen, Y. Shyr, W. Yin, J. Li, Jie He, Luhua Wang (2017)

Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial

Annals of Oncology, 28

( MorgenszternD NgSH GaoF GovindanR . Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5:29-33.19952801)

MorgenszternD NgSH GaoF GovindanR . Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5:29-33.19952801

MorgenszternD NgSH GaoF GovindanR . Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5:29-33.19952801, MorgenszternD NgSH GaoF GovindanR . Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5:29-33.19952801

H. Al-Halabi, K. Sayegh, Subba Digamurthy, A. Niemierko, Z. Piotrowska, H. Willers, L. Sequist (2015)

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy

Journal of Thoracic Oncology, 10

( LiangJ BiN WuS , et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28:777-783.28137739)

LiangJ BiN WuS , et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28:777-783.28137739, LiangJ BiN WuS , et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28:777-783.28137739

P. Iyengar, Z. Wardak, D. Gerber, V. Tumati, C. Ahn, R. Hughes, J. Dowell, Naga Cheedella, L. Nedzi, K. Westover, S. Pulipparacharuvil, H. Choy, R. Timmerman (2018)

Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

JAMA Oncology, 4

D. Morgensztern, Shean Ng, F. Gao, R. Govindan (2010)

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey

Journal of Thoracic Oncology, 5

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenègre, B. Massutí, E. Felip, R. Palmero, R. García-Gómez, C. Pallarés, J. Sánchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Morán, A. Insa, F. Marinis, R. Corre, I. Bover, A. Illiano, É. Dansin, J. Castro, M. Milella, N. Reguart, G. Altavilla, U. Jiménez, M. Provencio, M. Moreno, J. Terrasa, J. Muñoz-Langa, J. Valdivia, D. Isla, M. Dómine, O. Molinier, J. Mazières, N. Baize, R. García-Campelo, G. Robinet, D. Rodríguez-Abreu, G. López-Vivanco, V. Gebbia, Lioba Ferrera-Delgado, P. Bombaron, R. Bernabé, A. Bearz, Á. Artal, E. Cortesi, C. Rolfo, M. Sánchez-Ronco, A. Drozdowskyj, C. Queralt, I. Aguirre, J. Ramírez, J. Sánchez, M. Molina, M. Taron, L. Paz-Ares (2012)

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

The Lancet. Oncology, 13 3

( ZhengL WangY XuZ , et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist. 2019;24:1031-e612.)

ZhengL WangY XuZ , et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist. 2019;24:1031-e612.

ZhengL WangY XuZ , et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist. 2019;24:1031-e612., ZhengL WangY XuZ , et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist. 2019;24:1031-e612.

Jin-Ji Yang, Caicun Zhou, Yi-sheng Huang, Jifeng Feng, Sun Lu, Yong Song, Cheng Huang, Gang Wu, Li Zhang, Ying Cheng, Chengping Hu, Gongyan Chen, Li Zhang, Xiaoqing Liu, Hong-Hong Yan, Fen-lai Tan, W. Zhong, Yi-long Wu (2017)

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

The Lancet. Respiratory medicine, 5 9

( MagnusonWJ Lester-CollNH WuAJ , et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol. 2017;35:1070-1077.28113019)

MagnusonWJ Lester-CollNH WuAJ , et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol. 2017;35:1070-1077.28113019, MagnusonWJ Lester-CollNH WuAJ , et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol. 2017;35:1070-1077.28113019

Y. Elamin, D. Gomez, M. Antonoff, J. Robichaux, H. Tran, Melissa Shorter, Jadi Bohac, M. Negrão, X. Le, Waree Rinsurogkawong, J. Lewis, Lara Lacerda, Emily Roarty, S. Swisher, J. Roth, Jianjun Zhang, V. Papadimitrakopoulou, J. Heymach (2019)

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small‐cell Lung Cancer (NSCLC)

Clinical Lung Cancer, 20

Ravi Parikh, A. Cronin, D. Kozono, G. Oxnard, R. Mak, D. Jackman, Peter Lo, E. Baldini, B. Johnson, Aileen Chen (2014)

Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.

International journal of radiation oncology, biology, physics, 89 4

Yi-long Wu, Caicun Zhou, Cheng-ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, M. Hou, Jianhua Shi, K. Lee, Chongrui Xu, D. Massey, Miyoung Kim, Yang Shi, Sarayut Geater (2014)

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

The Lancet. Oncology, 15 2

Suchit Patel, A. Rimner, A. Foster, Zhigang Zhang, K. Woo, H. Yu, Gregory Riely, A. Wu (2017)

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

Lung cancer, 108

( PengP ChenY HanG , et al. MA01.09 concomitant SBRT and EGFR-TKI versus EGFR-TKI alone for oligometastatic NSCLC: a multicenter, randomized phase II study. J Thorac Oncol. 2019;14:S250-S251.)

PengP ChenY HanG , et al. MA01.09 concomitant SBRT and EGFR-TKI versus EGFR-TKI alone for oligometastatic NSCLC: a multicenter, randomized phase II study. J Thorac Oncol. 2019;14:S250-S251.

PengP ChenY HanG , et al. MA01.09 concomitant SBRT and EGFR-TKI versus EGFR-TKI alone for oligometastatic NSCLC: a multicenter, randomized phase II study. J Thorac Oncol. 2019;14:S250-S251., PengP ChenY HanG , et al. MA01.09 concomitant SBRT and EGFR-TKI versus EGFR-TKI alone for oligometastatic NSCLC: a multicenter, randomized phase II study. J Thorac Oncol. 2019;14:S250-S251.

F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA: A Cancer Journal for Clinicians, 68

( CampoM Al-HalabiH KhandekarM ShawAT SequistLV WillersH . Integration of stereotactic body radiation therapy with tyrosine kinase inhibitors in stage IV oncogene-driven lung cancer. Oncologist. 2016;21:964-973.27354669)

CampoM Al-HalabiH KhandekarM ShawAT SequistLV WillersH . Integration of stereotactic body radiation therapy with tyrosine kinase inhibitors in stage IV oncogene-driven lung cancer. Oncologist. 2016;21:964-973.27354669, CampoM Al-HalabiH KhandekarM ShawAT SequistLV WillersH . Integration of stereotactic body radiation therapy with tyrosine kinase inhibitors in stage IV oncogene-driven lung cancer. Oncologist. 2016;21:964-973.27354669

P. Peng, Y. Chen, G. Han, R. Meng, S. Zhang, Z. Liao, Yi Zhang, J. Gong, C. Xiao, X. Liu, Pengfei Zhang, Liao Zhang, Shu Xia, Q. Chu (2019)

MA01.09 Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study

Journal of Thoracic Oncology

Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer (2019 ASCO annual meeting)

( GomezDR BlumenscheinGRJr LeeJJ , et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672-1682.27789196)

GomezDR BlumenscheinGRJr LeeJJ , et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672-1682.27789196, GomezDR BlumenscheinGRJr LeeJJ , et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672-1682.27789196

( ParikhRB CroninAM KozonoDE , et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol. 2014;89:880-887.)

ParikhRB CroninAM KozonoDE , et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol. 2014;89:880-887.

ParikhRB CroninAM KozonoDE , et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol. 2014;89:880-887., ParikhRB CroninAM KozonoDE , et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol. 2014;89:880-887.

P. Borghetti, M. Bonù, E. Roca, Sara Pedretti, E. Salah, A. Baiguini, D. Greco, L. Triggiani, M. Maddalo, N. Levra, F. Alongi, S. Magrini, M. Buglione (2018)

Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience.

In vivo, 32 1

( RosellR CarcerenyE GervaisR , et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.22285168)

RosellR CarcerenyE GervaisR , et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.22285168, RosellR CarcerenyE GervaisR , et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.22285168

A. Ardizzoni, L. Boni, M. Tiseo, F. Fossella, J. Schiller, M. Paesmans, D. Radosavljević, A. Paccagnella, P. Zatloukal, P. Mazzanti, D. Bisset, R. Rosell (2007)

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

Journal of the National Cancer Institute, 99 11

P. Gray, R. Mak, B. Yeap, Sarah Cryer, N. Pinnell, Laura Christianson, D. Sher, Nils Arvold, E. Baldini, Aileen Chen, D. Kozono, S. Swanson, D. Jackman, B. Alexander (2014)

Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.

Lung cancer, 85 2

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer:

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer: